Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A, Beeharry N, Imbrogno E, Ferrari A, Robustelli V, Righi S, Sabattini E, Verga Falzacappa MV, Ronchini C, Testoni N, Baldazzi C, Papayannidis C, Abbenante MC, Marconi G, Paolini S, Parisi S, Sartor C, Fontana MC, De Matteis S, Iacobucci I, Pelicci PG, Cavo M, Yen TJ, Martinelli G. Ghelli Luserna Di Rorà A, et al. Among authors: robustelli v. J Hematol Oncol. 2018 Aug 1;11(1):99. doi: 10.1186/s13045-018-0641-1. J Hematol Oncol. 2018. PMID: 30068368 Free PMC article.
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A, Iacobucci I, Imbrogno E, Papayannidis C, Derenzini E, Ferrari A, Guadagnuolo V, Robustelli V, Parisi S, Sartor C, Abbenante MC, Paolini S, Martinelli G. Ghelli Luserna Di Rorà A, et al. Among authors: robustelli v. Oncotarget. 2016 Aug 16;7(33):53377-53391. doi: 10.18632/oncotarget.10535. Oncotarget. 2016. PMID: 27438145 Free PMC article.
Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia.
Ghelli Luserna Di Rorà A, Bocconcelli M, Ferrari A, Terragna C, Bruno S, Imbrogno E, Beeharry N, Robustelli V, Ghetti M, Napolitano R, Chirumbolo G, Marconi G, Papayannidis C, Paolini S, Sartor C, Simonetti G, Yen TJ, Martinelli G. Ghelli Luserna Di Rorà A, et al. Among authors: robustelli v. Cancers (Basel). 2019 Oct 25;11(11):1654. doi: 10.3390/cancers11111654. Cancers (Basel). 2019. PMID: 31717700 Free PMC article.
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia.
Bruno S, Bochicchio MT, Franchini E, Padella A, Marconi G, Ghelli Luserna di Rorà A, Venturi C, Raffini M, Prisinzano G, Ferrari A, Bandini L, Robustelli V, Pazzaglia M, Fontana MC, Sartor C, Abbenante MC, Papayannidis C, Soverini S, Ottaviani E, Simonetti G, Martinelli G. Bruno S, et al. Among authors: robustelli v. J Oncol. 2019 Oct 30;2019:5985923. doi: 10.1155/2019/5985923. eCollection 2019. J Oncol. 2019. PMID: 31827512 Free PMC article.
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Papayannidis C, Sartor C, Dominietto A, Zappone E, Arpinati M, Marconi G, Cristiano G, Nanni J, Parisi S, Barbato F, Paolini S, Soverini S, Terragna C, Robustelli V, Testoni N, Chirumbolo G, Curti A, Cavo M, Bonifazi F. Papayannidis C, et al. Among authors: robustelli v. Hematol Oncol. 2021 Oct;39(4):580-583. doi: 10.1002/hon.2886. Epub 2021 May 7. Hematol Oncol. 2021. PMID: 33963566 No abstract available.
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
Sartor C, Arpinati M, Chirumbolo G, Dozza L, Cristiano G, Nanni J, Marconi G, Robustelli V, Vigliotta I, Parisi S, Terragna C, Testoni N, Paolini S, Martinelli G, Curti A, Cavo M, Papayannidis C. Sartor C, et al. Among authors: robustelli v. Hematol Oncol. 2022 Oct;40(4):734-742. doi: 10.1002/hon.3029. Epub 2022 Jun 5. Hematol Oncol. 2022. PMID: 35618655
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, Bochicchio MT, Paganelli M, Robustelli V, Sanogo S, Cerchione C, Fumagalli M, Rondoni M, Imovilli A, Musuraca G, Martinelli G, Simonetti G. Ghelli Luserna Di Rorà A, et al. Among authors: robustelli v. Cell Biol Toxicol. 2023 Jun;39(3):795-811. doi: 10.1007/s10565-021-09640-x. Epub 2021 Sep 14. Cell Biol Toxicol. 2023. PMID: 34519926 Free PMC article.
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.
Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, Marconi G, Lemoli RM, Guolo F, Fornaro A, Lunghi M, de Fabritiis P, Candoni A, Selleri C, Simonetti F, Bocchia M, Vitale A, Frison L, Tedeschi A, Cuneo A, Bonifacio M, Martelli MP, D'Ardia S, Trappolini S, Tosi P, Galieni P, Fabbiano F, Abbenante MC, Granier M, Zhu Z, Wang M, Sartor C, Paolini S, Cavo M, Foà R, Fazi P, Vignetti M, Baccarani M. Martinelli G, et al. Among authors: robustelli v. Blood Adv. 2022 Mar 22;6(6):1742-1753. doi: 10.1182/bloodadvances.2021004821. Blood Adv. 2022. PMID: 34649276 Free PMC article.
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.
Bruno S, Bandini L, Patuelli A, Robustelli V, Venturi C, Mancini M, Forte D, De Santis S, Monaldi C, Grassi A, Chiurumbolo G, Paolini S, Cristiano G, Papayannidis C, Sartor C, Nanni J, Ottaviani E, Curti A, Cavo M, Soverini S. Bruno S, et al. Among authors: robustelli v. Front Oncol. 2021 Sep 30;11:728613. doi: 10.3389/fonc.2021.728613. eCollection 2021. Front Oncol. 2021. PMID: 34660293 Free PMC article.
17 results